Pharmaceutical composition for prevention of diet induced obesity
The present invention relates to a pharmaceutical composition/formulation for the prevention of diet induced obesity. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Oleoylethanolamide (OEA) and other natural ingredients can be used for treatment of obesity and its related disorders associated with fat metabolism like non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD). This can also be helpful in controlling obesity by way of maintaining body weight. The invention also provides various formulations and methods of preparing the same.
1. A pharmaceutical composition comprising a combination of:
Oleoylethanolamide (OEA) ranging from 10 to 70% by wt. of the composition;
naturally occurring β-aminoisobutyric acid (BAIBA) ranging from 2 to 60% by wt. of the composition, and selected from the group consisting of valine, iso-leucine and combinations thereof; and
natural anti-oxidant ranging from 20 to 35% by wt. of the composition, and selected from the group consisting of vitamin E, glutathione, pantethine, fucoxanthin and combinations thereof,
wherein the pharmaceutical composition provides a synergistic effect as compared to the OEA alone, the naturally occurring BAIBA alone, or the natural anti-oxidant alone.
2. The pharmaceutical composition as claimed in claim 1 , comprising Oleoylethanolamide (OEA), valine and pantethine.
3. The pharmaceutical composition as claimed in claim 1 , wherein the composition further comprises natural alpha-glucosidase inhibitor, naturally occurring fatty acid amine hydrolase (FAAH) inhibitor or combination thereof.
4. The pharmaceutical composition as claimed in claim 3 , wherein the natural alpha-glucosidase inhibitor is 1-deoxynojirimycin.
5. The pharmaceutical composition as claimed in claim 3 , comprising from 0.5% to 1.5% by wt., of the composition, of the natural alpha-glucosidase inhibitor.
6. The pharmaceutical composition as claimed in claim 3 , wherein the natural FAAH Inhibitor is Quercetin, Myricetin, Isorhamnetin, Kaempferol, Pristimerin, Curcumin, Biochanin A, Genistein, Daidzein or combination thereof.
7. The pharmaceutical composition as claimed in claim 3 , comprising from 0.5% to 25% by wt., of the composition, of the natural FAAH inhibitor.
8. The pharmaceutical composition as claimed in claim 1 , further comprising a pharmaceutically acceptable excipient.
9. The pharmaceutical composition as claimed in claim 8 , wherein the pharmaceutically acceptable excipient is diluent, binder, lubricant, glidant or solvent.
10. The pharmaceutical composition as claimed in claim 9 ,
comprising from 1% to 30% by wt., of the composition, of the diluent,
from 0.5% to 1.5% by wt., of the composition, of the binder,
from 0.5% to 5% by wt., of the composition, of the lubricant,
from 1.0% to 25% by wt., of the composition, of the glidant, or
the solvent is quantity sufficient.
11. The pharmaceutical composition as claimed in claim 1 , wherein the composition is in the form of a tablet, capsule, sachet, pill, hard capsule filled with liquid or solid, soft capsule, powder, granule, suspension, solution or modified release formulation.
12. A process for preparing a pharmaceutical composition comprising a combination of: Oleoylethanolamide (OEA) ranging from 10 to 70% by wt. of the composition; naturally occurring β-aminoisobutyric acid (BAIBA) ranging from 2 to 60% by wt. of the composition, and selected from the group consisting of valine, iso-leucine and combinations thereof, and natural anti-oxidant ranging from 20 to 35% by wt. of the composition, and selected from the group consisting of vitamin E, glutathione, pantethine, fucoxanthin and combinations thereof, wherein the pharmaceutical composition provides a synergistic effect as compared to the OEA alone, the naturally occurring BAIBA alone, or the natural anti-oxidant alone, the process comprising the steps of:
a. independently, sifting the OEA, the naturally occurring BAIBA, the natural anti-oxidant, a diluent, and a glidant,
b. mixing the product of step a,
c. adding a binder solution to step b to provide a dough, and sieving the dough to obtain granules,
d. drying the granules until the level of dryness (LOD) is reduced to less than 1.5% w/w to provide semi-dried granules,
e. sifting the semi-dried granules through a suitable sieve, and
f. sifting a lubricant or glidant separately through a suitable sieve and adding the lubricant or glidant to the product of step e.